Search | Clinical Trials Finder

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
Interventions: Not listed
Lead sponsor: Cosmos Rx, Inc; Industry
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lung Disease, Chronic Obstructive, Lung Disease, Interstitial
Interventions: Not listed
Lead sponsor: Echosense Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis Interstitial Lung Disease
Interventions: Pirfenidone, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
Interventions: MoblO2 controls O2 flow, MoblO2 does not control flow; Other
Lead sponsor: Minnesota HealthSolutions; Industry
Eligibility: 25 Years to 95 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Home Exercise Program, Aerobic Plus Strength Training, Home Exercise Program, Aerobic Only; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Interstitial Lung Diseases
Interventions: Hyperpolarized 129Xe; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Systemic Sclerosis (SSc), Scleroderma
Interventions: Tibulizumab, Placebo; Biological · Other
Lead sponsor: Zura Bio Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Interventions: ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator; Device · Procedure
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Riverside, California + 29 more

Conditions: Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: INOpulse®, Placebo, Open Label Extension; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 49 more

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more

Conditions: Systemic Sclerosis
Interventions: Pirfenidone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more

Conditions: Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Interstitial Pneumonitis, Desquamative Interstitial Pneumonia
Interventions: Aerobic Exercise Training (AET), Education; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 21 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Bethesda, Maryland • Falls Church, Virginia

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: SUPPORT-T Educational Intervention; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Sarcoidosis, Pulmonary Arterial Hypertension
Interventions: Iloprost; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Interstitial Lung Disease
Interventions: [68Ga]CBP8, Dotarem; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Sclerosis With and Without Interstitial Lung Disease
Interventions: MK-2225, Placebo; Biological
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Asthma, Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Interventions: Capnography; Procedure
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more

Conditions: Scleroderma Lung
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Interstitial Lung Disease
Interventions: Cryobiopsy biopsy, Transbronchial Biopsy, VATS biopsy; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: LIQ861; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 23
States / cities: Phoenix, Arizona • Fresno, California • La Jolla, California + 20 more

Search by objective public record fields.

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension

High Resolution Micro OCT Imaging

Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)

Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

MoblO2 to Maintain Oxygenation

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease

SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Use Of Capnography As Surrogate Measure Of PC02 In Medical Intensive Care Unit (ICU) Patients

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough

Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH